Fleury (FLRY3) Q3 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2024 earnings summary
14 Jul, 2026Executive summary
Gross revenue reached R$2.13 billion in 3Q24, up 6.1% year-over-year, with EBITDA of R$537.4 million (6.2% growth) and net income of R$190.7 million (9.5% growth), reflecting strong execution and integration of Grupo Pardini and Hermes Pardini, and expansion in B2B and mobile services.
Consolidated net revenue for the nine months ended September 30, 2024, was R$5.85 billion, up 22.7% year-over-year, driven by organic growth, acquisitions (São Lucas, Gênesis JV), and new business lines.
Net income attributable to shareholders was R$532.3 million for the nine months, a 55.4% increase year-over-year, reflecting improved operational performance and scale.
The company maintained a robust capital structure, with a leverage ratio of 1.0x net debt/EBITDA and extended debt maturity to 3.4 years.
Multiple industry awards and recognition reinforce leadership in the Brazilian healthcare sector.
Financial highlights
Gross revenue: R$2.13 billion (+6.1% YoY) in 3Q24; net revenue: R$1.96 billion (+5.0% YoY); EBITDA: R$537.4 million (+6.2% YoY), margin 27.4% (+32 bps); net income: R$190.7 million (+9.5% YoY), margin 9.7% (+40 bps).
Gross profit for 3Q24 was R$557.0 million (+5.6% YoY), gross margin 28.4% (+17 bps); operating income before financial results and taxes was R$996.8 million for the nine months (+36.4% YoY).
Operational cash flow in 3Q24 was R$558.7 million (+16.2% YoY); capex: R$112.7 million (+29.1% YoY), focused on IT/digital and technical areas.
Net debt stood at R$1.87 billion, net debt/EBITDA at 1.0x, with average debt maturity of 3.4 years and recent debenture issuance extending average term to 4.2 years at CDI +0.95%.
Earnings per share (basic and diluted) for the nine months were R$0.98, compared to R$0.71 in the prior year.
Outlook and guidance
Management expects continued disciplined execution, innovation, and digital evolution, with a focus on expanding B2B Lab-to-Lab, digital health platforms, and new regions.
Integration with Pardini Group progressing, with further synergies expected in technical platforms and supplier contracts.
No formal guidance provided, but management expects ongoing resiliency and growth opportunities, especially in intermediate segments and mobile services.
Latest events from Fleury
- Net income up 47.5% and EBITDA margin expands to 26.4% on strong B2C and B2B growth.FLRY3
Q2 202414 Jul 2026 - Revenue and net profit rose over 6%, with strong digital and regional growth, and low leverage.FLRY3
Q1 202514 Jul 2026 - Revenue up 2.8% with stable EBITDA margin; net income fell on higher costs and depreciation.FLRY3
Q2 202514 Jul 2026 - Q3 2025 saw 11.5% revenue growth, stable margins, and continued expansion via acquisitions.FLRY3
Q3 202514 Jul 2026 - Double-digit revenue and EBITDA growth in 4Q25, led by B2C and strategic acquisitions.FLRY3
Q4 202514 Jul 2026 - Revenue up 10.1%, EBITDA up 10.7%, net income up 12.2%, led by B2C and regional growth.FLRY3
Q1 202614 Jul 2026 - Revenue up 19.5%, EBITDA up 19.6%, net income up 32%, with strong cash flow and ESG results.FLRY3
Q4 20242 Jul 2026 - Strong growth, expanded reach, and robust ESG drive leadership in Brazilian diagnostic medicine.FLRY3
Investor presentation16 Feb 2026